ANN ARBOR, Mich., June 7, 2021 /PRNewswire/ -- Swift Biosciences, pioneers in the development of library preparation and targeted sequencing solutions for next generation sequencing (NGS) in research applications, has announced the release of Swift 2S™ Turbo v2 DNA Library Kits for whole genome and whole exome studies.
Swift 2S™Turbo v2 includes a specially formulated PCR Master Mix that boosts a minimal number of PCR cycles. This produces high yields with fewer PCR duplicates due to redesigned adapter and master mix components.
The streamlined protocol is available in two formats for adapter and indexing flexibility. This technology leverages rapid and highly reproducible fragmentation and library construction, enabling manual and fully automatable workflows that are compatible with Swift Normalase™ technology.
"Swift's Automation FAS team is available to assist with virtual deployment of Turbo v2 on a number of automated platforms," said Francesco Criscuolo, a lead automation specialist at Swift Biosciences. "I encourage everyone to take advantage of our resources, which effectively reduce hands-on time and enable higher output efficiencies."
The new NGS solutions are already finding support from those working in the industry.
"The new master mix in Turbo v2 generates higher yields of excellent quality libraries," said Eric Crowder, an NGS process engineer at Inscriptia, Inc. "We adopted this technology because it's designed for automation: we are able to achieve precise dispensing without worrying about a lack of reagents or sufficient overfill. The new PCR master mix allows use of fixed-tip automation solutions in post-PCR processing. We recommend this technology to anyone using automation for whole genome library preparation."
Swift recently merged with Iowa-based Integrated DNA Technologies (IDT).
About Swift Biosciences
Swift Biosciences , now part of Integrated DNA Technologies, Inc., develops and commercializes research-use-only (RUO) next generation sequencing library preparation kits for a variety of applications. Their tools reduce sequencing costs for researchers and provide the most comprehensive coverage available on the market.
For more information, visit SwiftBioSci.com and follow Swift Biosciences on Twitter (@SwiftBioSci).
For research use only. Not for use in diagnostic procedures. Unless otherwise agreed to in writing, IDT does not intend these products to be used in clinical applications and does not warrant their fitness or suitability for any clinical diagnostic use. Purchaser is solely responsible for all decisions regarding the use of these products and any associated regulatory or legal obligations.
Media Contact: Camille Cappello 858.220.8521 [email protected]
SOURCE Swift Biosciences
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article